Oxford BioDynamics’ Study on Predictive Cancer Test: Market Implications

Oxford BioDynamics ((GB:OBD)) announced an update on their ongoing clinical study.

Oxford BioDynamics is conducting a study titled A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. The study aims to assess the effectiveness of the Episwitch CiRT® test in predicting cancer patients’ responses to PD-(L)-1 checkpoint inhibitors, a type of immunotherapy.

The intervention being tested is the Episwitch CiRT®, a blood-based 3D genome conformation mapping test. Its purpose is to predict the likelihood of a patient’s response to PD-(L)-1 checkpoint inhibitors, which are used in treating various cancers.

This observational study follows a cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on real-world evidence to determine the test’s predictive accuracy.

The study began on September 5, 2024, with its latest update submitted on March 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.

The study’s findings could significantly impact Oxford BioDynamics’ stock performance by validating the Episwitch CiRT® test’s utility. Positive results might enhance investor confidence and position the company favorably against competitors in the cancer diagnostics market.

The study is currently ongoing, with further details available on the ClinicalTrials portal.